Substance / Medication

Plicamycin

Overview

Active Ingredient
plicamycin
RxNorm CUI
6995

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
1
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
1,25-dihydroxyvitamin D-mediated hypercalcemia associated with solid organ malignancy: a systematic review.
Charoenngam Nipith, Ponvilawan Ben, Rujirachun Pongprueth et al. · Minerva Endocrinol (Torino) · 2025
PMID: 34581546Meta-Analysis
Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
Bassatne Aya, Murad Mohammad H, Piggott Thomas et al. · J Clin Endocrinol Metab · 2023
PMID: 36545699Meta-Analysis
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
El-Hajj Fuleihan Ghada, Clines Gregory A, Hu Mimi I et al. · J Clin Endocrinol Metab · 2023
PMID: 36545746Meta-Analysis
Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials.
Zittermann Armin, Trummer Christian, Theiler-Schwetz Verena et al. · Eur J Nutr · 2023
PMID: 36853379Meta-AnalysisFull text (PMC)
Long-term Recurrence Rates After Surgery in Primary Hyperparathyroidism.
Zaman Muizz, Raveendran Laxshika, Senay Ayla et al. · J Clin Endocrinol Metab · 2023
PMID: 37279502Meta-Analysis
Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.
Nair Rajesh R, Piktel Debbie, Geldenhuys Werner J et al. · Leuk Res · 2018
PMID: 30103201OtherFull text (PMC)
Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.
Deng Jiayin, Tian Ai-Ling, Pan Hui et al. · Cell Death Dis · 2021
PMID: 34675191PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Plicamycin (substance)
SNOMED CT
387101002
UMLS CUI
C0026234
RxNorm CUI
6995

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.